SCHEMBL3246275

SCHEMBL3246275

Fc1ccccc1-c1[c]c2ccccc2cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.37
CYP1A1 P04798 3/20 0.36
CYP1A2 P05177 3/20 0.36
CYP1B1 Q16678 3/20 0.36
AHR P35869 1/20 0.36
PRKDC P78527 1/20 0.36
MBNL1 Q9NR56 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
DCUN1D1 Q96GG9 2/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
MPL P40238 1/20 0.33
BACE1 P56817 1/20 0.33
PKM P14618 2/20 0.33
RAB9A P51151 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239122 0.79 CYP2A6 (0.37) CYP1A1CYP1A2CYP1B1ALDH1A1
SCHEMBL668159 0.77 ALDH1A1 (0.41) CYP1A2CYP1B1L3MBTL1ALDH1A1NFKB1
SCHEMBL667984 0.77 ALDH1A1 (0.34) DCUN1D1BACE1RAB9AALDH1A1MEN1
SCHEMBL10501303 0.77 ALDH1A1 (0.39) NPC1CYP1A2L3MBTL1DCUN1D1CASP3
SCHEMBL4609078 0.77 MAPK1 (0.39) L3MBTL1DCUN1D1RAB9AALDH1A1NFKB1
SCHEMBL3249728 0.77 ALDH1A1 (0.34) NPC1CYP1A2DCUN1D1CASP3SENP8
SCHEMBL3240933 0.77 CYP2A6 (0.39) NPC1CYP1A1CYP1A2CYP1B1L3MBTL1
SCHEMBL1978337 0.77 HSD11B1 (0.38) CYP1A2BACE1ALDH1A1MAPK1NOTUM
SCHEMBL16697744 0.76 ALDH1A1 (0.35) L3MBTL1ALDH1A1MAPK1
SCHEMBL668632 0.74 ALDH1A1 (0.38) CYP1A2CYP1B1L3MBTL1ALDH1A1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101977883-A Process for production of 2-hydroxyaryl aldehyde compound NISSAN CHEMICAL IND LTD 2011-02-16 CN disclosed
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 NPC1 359/4885CYP1A1 699/4885CYP1A2 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.